--- title: "如瑞迪博士在印度推出了針對 2 型糖尿病患者的口服藥物 Obeda" type: "News" locale: "zh-HK" url: "https://longbridge.com/zh-HK/news/287073753.md" description: "藥明康德推出了 Obeda，一種用於 2 型糖尿病患者的口服賽美特肽生物仿製藥，已在印度上市。這種每日一次的藥片旨在改善血糖控制，並在此之前推出了賽美特肽的注射劑。印度中央藥品標準控制組織（CDSCO）在一項 III 期研究顯示其療效和安全性與創新藥物相當後批准了 Obeda。該藥品提供三種劑量，價格從每片 99 盧比到 225 盧比不等。首席執行官 M V Ramana 強調了對印度糖尿病護理質量和供應可靠性的承諾" datetime: "2026-05-20T05:18:36.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287073753.md) - [en](https://longbridge.com/en/news/287073753.md) - [zh-HK](https://longbridge.com/zh-HK/news/287073753.md) --- # 如瑞迪博士在印度推出了針對 2 型糖尿病患者的口服藥物 Obeda Dr. Reddy’s Laboratories has announced the commercial launch of its oral semaglutide biosimilar under the brand name Obeda in India. The once-daily prescription tablet is indicated as an adjunct to diet and exercise to improve glycaemic control in adults living with type 2 diabetes mellitus. The launch follows the company’s recent introduction of generic semaglutide injections in India and Canada, expanding its portfolio of glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapies. According to data cited from the ICMR-INDIAB study, India faces a significant metabolic disease burden, with more than 101 million adults diagnosed with diabetes, an 11.4 per cent prevalence rate, and approximately 136 million individuals classified as prediabetic. The Central Drugs Standard Control Organisation (CDSCO) granted marketing approval for Obeda following a review of data from a Phase III clinical study conducted in India. The trial enrolled 288 participants with type 2 diabetes. According to the company’s regulatory filing, the clinical study demonstrated non-inferior efficacy and a comparable safety profile to the innovator oral drug. The trial measured parameters including fasting and post-prandial plasma glucose, weight reduction, and the proportion of participants achieving an HbA1c level below 7 per cent at 12 and 24 weeks. Additionally, the study reported that no anti-drug antibodies were detected, indicating an immunogenicity profile comparable to the reference product. Obeda is formulated using a recombinant DNA (rDNA)-origin active pharmaceutical ingredient (API), developed and manufactured in-house by Dr. Reddy’s. The medication is available in three distinct strengths to allow flexible dosing, with pricing structured by dosage. The lowest strength, 3 mg, is priced at Rs 99 per tablet. The mid-range 7 mg dose is available at Rs 135 per tablet, while the highest strength of 14 mg is priced at Rs 225 per tablet. “The launch of our oral semaglutide for patients with diabetes marks an important step in our journey to broaden access to advanced diabetes care,” said M V Ramana, chief executive officer, Global Generics, at Dr. Reddy’s. “As the product is developed and formulated in-house, we are committed to reliable supply and consistent quality for patients in India.” The company stated that the in-house manufacturing structure is designed to secure supply-chain reliability for the chronic metabolic disease market in India and potentially other emerging regions. As a prescription-only medication, patients are advised to consult medical professionals regarding treatment regimens. ### 相關股票 - [RDY.US](https://longbridge.com/zh-HK/quote/RDY.US.md) ## 相關資訊與研究 - [鉅亨速報 - Factset 最新調查：如瑞迪博士 ADR(RDY-US) EPS 預估下修至 0.55 元，預估目標價為 13.27 元](https://longbridge.com/zh-HK/news/286277853.md) - [鉅亨速報 - Factset 最新調查：如瑞迪博士 ADR(RDY-US) EPS 預估下修至 0.64 元，預估目標價為 13.44 元](https://longbridge.com/zh-HK/news/286098145.md) - [塔塔電子攜手艾司摩爾 打造印度首座晶圓廠](https://longbridge.com/zh-HK/news/286672132.md) - [中信銀印度 GIFT City 分行正式開幕 拓展跨境金融創新里程碑](https://longbridge.com/zh-HK/news/286749393.md) - [復宏漢霖：注射用 HLX43 用於治療晚期非小細胞肺癌的國際多中心 2 期臨牀研究完成首例患者給藥](https://longbridge.com/zh-HK/news/287195179.md)